Summit Therapeutics Inc. ("Summit," "we," or the "Company") today announced that it has submitted a Biologics License ...

Summit Therapeutics Inc. today announced it has entered into a clinical trial collaboration with GSK plc ("GSK", LSE/NYSE: GSK) to evaluate ivonescimab, a novel, investigational PD-1 / VEGF bispecific ...

CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for ...

Smoking tobacco is known to worsen symptoms of periodontitis and reduce responsiveness to treatment. Using high-resolution ...

New research has identified that neuroinflammation driven by microglia (immune cells in the brain) is a primary underlying ...

The AI model "Eden" is intended to generate new gene therapies for cancer and rare diseases, as well as active ingredients ...

The 921-piece mid-scale display model of the Millennium Falcon is available for only $68.

On Dec. 16, I testified before the House Judiciary Subcommittee at a hearing titled “Anti-American Antitrust: How Foreign ...

The use of personal data to target minors, combined with opaque algorithms and engagement-driven design, has heightened fears ...

The political situation may be uncertain but that makes it even more important for brands to be proactive and identify trends ...

Highwood Asset Management Ltd., ("Highwood" or the "Company") (TSXV: HAM) is pleased to announce an operational update ...

Jan 12 () - Swiss drugmaker Novartis has signed a licensing deal worth nearly $1.7 billion with privately held SciNeuro ...